Investors Sought in Lawsuit Alleging Phreesia Misled on Pharma-Driven Growth

Overview

• A complaint filed by investor plaintiffs alleges Phreesia made false and misleading statements about its long-term growth outlook and fiscal 2027 projections by overstating the role of pharmaceutical marketing commitments in its Network Solutions segment.
• Plaintiffs say the market reacted when the alleged problems surfaced and that investors who bought shares during the identified class period suffered losses after the company revealed weaker-than-expected pharmaceutical commitments.
• The Schall Law Firm issued a public notice inviting eligible shareholders to join the lawsuit and to seek lead-plaintiff status, and the firm set a contact deadline of July 13, 2026 for potential participants.
• The case invokes Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5, and the class remains uncertified so shareholders are not yet represented by counsel unless they affirmatively sign on.
• If appointed lead plaintiff, an investor would steer litigation strategy and could pursue recovery for alleged losses, and the outcome could affect how companies disclose reliance on third-party commercial commitments in future growth forecasts.